Cambrian is awarded up to $30.8M from ARPA-H's PROSPR program to advance an mTORC1-selective inhibitor

Cambrian Bio/Pipeline companies

ARPA-H's PROSPR programme awarded Cambrian up to $30.8M to develop selective mTORC1 inhibitors from its TORnado platform, designed to preserve healthspan benefits of mTOR inhibition while avoiding mTORC2 side effects.

• TORnado platform targets mTORC1-selective inhibition to improve intrinsic capacity (physical and metabolic resilience) in aging.
• Selective mTORC1 inhibition aims to achieve healthspan benefits while avoiding safety liabilities from mTORC2 blockade.
• Award supports development for preventative medicine use in older populations where mTORC1 dysregulation drives metabolic decline.